Mastodon

Drill (Pastilles) Instructions for Use

Marketing Authorization Holder

Pierre Fabre Medicament Production (France)

ATC Code

R02A (Preparations for the treatment of throat diseases)

Active Substances

Chlorhexidine (Rec.INN registered by WHO)

Tetracaine (Rec.INN registered by WHO)

Dosage Form

Bottle OTC Icon Drill Medicinal lozenges (sugar-free) 0.2 mg+3 mg: 12 or 24 pcs.

Dosage Form, Packaging, and Composition

Sugar-free lozenges translucent, round in shape.

1 lozenge
Tetracaine hydrochloride 0.2 mg
Chlorhexidine digluconate 3 mg

Excipients: ascorbic acid – 52.5 mg, ammonium glycyrrhizinate – 5 mg, aspartame – 1 mg, isomalt – 2424.25 mg, flavor 1 – 9.55 mg, flavor 2 – 4.525 mg.

12 pcs. – blisters made of PVC/PVDF/aluminum foil (1) – cardboard packs.
12 pcs. – blisters made of PVC/PVDF/aluminum foil (2) – cardboard packs.

Clinical-Pharmacological Group

Drug with antimicrobial and local anesthetic action for topical use in ENT practice

Pharmacotherapeutic Group

Antiseptic + local anesthetic

Pharmacological Action

A combined drug that has antiseptic and anesthetic action for topical use in ENT practice.

The Chlorhexidine contained in the preparation has an antimicrobial effect against a wide range of gram-positive and gram-negative microorganisms. Furthermore, it also has an antifungal effect.

The Tetracaine contained in the preparation has a peripheral local anesthetic effect on the receptors of the oral and pharyngeal mucosa, which provides an anesthetic effect.

Pharmacokinetics

Due to low systemic absorption, data on the pharmacokinetics of Drill are not available.

Indications

  • Infectious and inflammatory diseases of the oral cavity and pharynx, not accompanied by fever, formation of aphthae, or violation of the integrity of the oral and pharyngeal mucosa.

ICD codes

ICD-10 code Indication
J02 Acute pharyngitis
J03 Acute tonsillitis
J31.2 Chronic pharyngitis
J35.0 Chronic tonsillitis
K05 Gingivitis and periodontal diseases
K12 Stomatitis and related lesions
ICD-11 code Indication
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA09.2 Chronic pharyngitis
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
DA01.Z Diseases of the oral mucosa, unspecified
DA0B.Z Gingival diseases, unspecified
DA0C.Z Periodontal diseases, unspecified
DA0Z Diseases or disorders of the orofacial complex, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

The lozenge is dissolved in the mouth until completely dissolved, but not swallowed.

The duration of treatment with Drill should not exceed 5 days.

An interval of at least 2 hours must be observed between doses of the drug.

After taking the drug, it is not recommended to: consume food and drinks, or brush teeth for the next 1-2 hours.

Adults and children over 15 years: 1 lozenge 4 times a day. Maximum daily dose – 4 lozenges.

Children from 6 to 15 years – 1 lozenge 2-3 times a day. Maximum daily dose – 3 lozenges.

Adverse Reactions

When using Drill for the approved indication and at recommended doses, the following adverse reactions may occur.

Immune system disorders: allergic reactions.

Skin and subcutaneous tissue disorders: skin rashes.

Gastrointestinal disorders: transient brown staining of the tongue and teeth; temporary numbness of the tongue and pharynx.

Contraindications

  • Hypersensitivity to any components of the drug;
  • History of allergic reactions to local anesthetics and Chlorhexidine;
  • Children under 6 years of age;
  • Phenylketonuria (the drug contains aspartame).

Use in Pregnancy and Lactation

There is limited data on the use of Drill during pregnancy and breastfeeding. Therefore, it is recommended to refrain from using the drug during pregnancy and breastfeeding.

Pediatric Use

Contraindicated in children under 6 years of age.

Special Precautions

Long-term use (more than 5 days) of the drug is undesirable due to the possible disruption of the normal microflora of the oral cavity and pharynx.

In case of worsening or no improvement in well-being after 5 days, it is recommended to consult a doctor.

After taking the drug, it is not recommended to: consume food and drinks, or brush teeth for the next 1-2 hours.

Drill should be used with particular caution by athletes because the active components of the drug can cause a positive reaction in anti-doping control tests.

Staining of teeth or composite filling material is not permanent and can largely be prevented by daily brushing with regular toothpaste, and in the case of dentures, by using conventional cleaning agents.

Patients with diabetes should take into account that 1 lozenge contains 0.2 bread units.

The energy value of 1 lozenge is 5.8 kcal.

In case of worsening of well-being or the appearance of unusual reactions, it is recommended to consult a doctor.

Effect on the ability to drive vehicles and machinery

Drill does not affect the ability to drive a car and other machinery.

Overdose

To date, no cases of overdose with Drill have been reported.

Drug Interactions

No clinically significant interaction of Drill with drugs of other groups has been identified.

Nevertheless, simultaneous or sequential administration of Drill and other local antiseptics (especially substances of anionic nature) is not recommended due to the possibility of interaction leading to antagonism, inactivation, and other manifestations of such interaction.

Storage Conditions

In a dry place at a temperature not exceeding 25°C (77°F). Keep out of reach of children.

Shelf Life

Shelf life – 3 years.

Dispensing Status

Over-the-counter.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS